KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Payables (2016 - 2025)

Historic Payables for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to $2.4 billion.

  • Amgen's Payables rose 2405.66% to $2.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.4 billion, marking a year-over-year increase of 2405.66%. This contributed to the annual value of $2.4 billion for FY2025, which is 2405.66% up from last year.
  • Per Amgen's latest filing, its Payables stood at $2.4 billion for Q4 2025, which was up 2405.66% from $2.8 billion recorded in Q3 2025.
  • Over the past 5 years, Amgen's Payables peaked at $3.0 billion during Q2 2025, and registered a low of $1.2 billion during Q3 2021.
  • Over the past 5 years, Amgen's median Payables value was $1.5 billion (recorded in 2022), while the average stood at $1.7 billion.
  • Per our database at Business Quant, Amgen's Payables crashed by 591.59% in 2023 and then soared by 8704.62% in 2024.
  • Over the past 5 years, Amgen's Payables (Quarter) stood at $1.4 billion in 2021, then rose by 15.08% to $1.6 billion in 2022, then increased by 1.15% to $1.6 billion in 2023, then rose by 20.0% to $1.9 billion in 2024, then rose by 24.06% to $2.4 billion in 2025.
  • Its Payables stands at $2.4 billion for Q4 2025, versus $2.8 billion for Q3 2025 and $3.0 billion for Q2 2025.